Skip to main content
PMC home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1998 Feb;7(2):259–269. doi: 10.1002/pro.5560070205

Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling.

T Piironen 1, B O Villoutreix 1, C Becker 1, K Hollingsworth 1, M Vihinen 1, D Bridon 1, X Qiu 1, J Rapp 1, B Dowell 1, T Lövgren 1, K Pettersson 1, H Lilja 1
PMCID: PMC2143911  PMID: 9521101

Abstract

Prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2), produced essentially by the prostate gland, are 237-amino acid monomeric proteins, with 79% identity in primary structure. Twenty-five anti-PSA monoclonal antibodies (Mabs) were studied for binding to a large array of synthetic linear peptides selected from computer models of PSA and hK2, as well as to biotinylated peptides covering the entire PSA sequence. Sixteen of the Mabs were bound to linear peptides forming four independent binding regions (I-IV). Binding region I was localized to amino acid residues 1-13 (identical sequence for PSA and hK2), II (a and b) was localized to residues 53-64, III (a and b) was localized to residues 80-91 (= kallikrein loop), and IV was localized to residues 151-164. Mabs binding to regions I and IIa were reactive with free PSA, PSA-ACT complex, and with hK2; Mabs binding to regions IIb, IIIa, and IV were reactive with free PSA and PSA-ACT complex, but unreactive with hK2; Mabs binding to region IIIb detected free PSA only. All Mabs tested (n = 7) specific for free PSA reacted with kallikrein loop (binding region IIIb). The presence of Mabs interacting with binding region I did not inhibit the catalytic activity of PSA, whereas Mabs interacting with other binding regions inhibited the catalysis. Theoretical model structures of PSA, hK2, and the PSA-ACT complex were combined with the presented data to suggest an overall orientation of PSA with regard to ACT.

Full Text

The Full Text of this article is available as a PDF (5.6 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Björk T., Piironen T., Pettersson K., Lövgren T., Stenman U. H., Oesterling J. E., Abrahamsson P. A., Lilja H. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology. 1996 Dec;48(6):882–888. doi: 10.1016/s0090-4295(96)00486-4. [DOI] [PubMed] [Google Scholar]
  2. Bridon D. P., Dowell B. L. Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling. Urology. 1995 May;45(5):801–806. doi: 10.1016/S0090-4295(99)80087-9. [DOI] [PubMed] [Google Scholar]
  3. Bélanger A., van Halbeek H., Graves H. C., Grandbois K., Stamey T. A., Huang L., Poppe I., Labrie F. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate. 1995 Oct;27(4):187–197. doi: 10.1002/pros.2990270403. [DOI] [PubMed] [Google Scholar]
  4. Catalona W. J., Smith D. S., Ratliff T. L., Dodds K. M., Coplen D. E., Yuan J. J., Petros J. A., Andriole G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991 Apr 25;324(17):1156–1161. doi: 10.1056/NEJM199104253241702. [DOI] [PubMed] [Google Scholar]
  5. Chapdelaine P., Paradis G., Tremblay R. R., Dubé J. Y. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett. 1988 Aug 15;236(1):205–208. doi: 10.1016/0014-5793(88)80315-6. [DOI] [PubMed] [Google Scholar]
  6. Christensson A., Björk T., Nilsson O., Dahlén U., Matikainen M. T., Cockett A. T., Abrahamsson P. A., Lilja H. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993 Jul;150(1):100–105. doi: 10.1016/s0022-5347(17)35408-3. [DOI] [PubMed] [Google Scholar]
  7. Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990 Dec 27;194(3):755–763. doi: 10.1111/j.1432-1033.1990.tb19466.x. [DOI] [PubMed] [Google Scholar]
  8. Deperthes D., Chapdelaine P., Tremblay R. R., Brunet C., Berton J., Hébert J., Lazure C., Dubé J. Y. Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma. Biochim Biophys Acta. 1995 Dec 14;1245(3):311–316. doi: 10.1016/0304-4165(95)00118-2. [DOI] [PubMed] [Google Scholar]
  9. Eerola R., Piironen T., Pettersson K., Lövgren J., Vehniäinen M., Lilja H., Dowell B., Lövgren T., Karp M. Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen. Prostate. 1997 May 1;31(2):84–90. doi: 10.1002/(sici)1097-0045(19970501)31:2<84::aid-pros2>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  10. España F., Gilabert J., Estellés A., Romeu A., Aznar J., Cabo A. Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res. 1991 Nov 1;64(3):309–320. doi: 10.1016/0049-3848(91)90002-e. [DOI] [PubMed] [Google Scholar]
  11. Greer J. Comparative modeling methods: application to the family of the mammalian serine proteases. Proteins. 1990;7(4):317–334. doi: 10.1002/prot.340070404. [DOI] [PubMed] [Google Scholar]
  12. Henttu P., Lukkarinen O., Vihko P. Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer. 1990 Apr 15;45(4):654–660. doi: 10.1002/ijc.2910450414. [DOI] [PubMed] [Google Scholar]
  13. Hudson M. A., Bahnson R. R., Catalona W. J. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol. 1989 Oct;142(4):1011–1017. doi: 10.1016/s0022-5347(17)38972-3. [DOI] [PubMed] [Google Scholar]
  14. Lawrence D. A. The serpin-proteinase complex revealed. Nat Struct Biol. 1997 May;4(5):339–341. doi: 10.1038/nsb0597-339. [DOI] [PubMed] [Google Scholar]
  15. Lilja H., Abrahamsson P. A., Lundwall A. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem. 1989 Jan 25;264(3):1894–1900. [PubMed] [Google Scholar]
  16. Lilja H., Christensson A., Dahlén U., Matikainen M. T., Nilsson O., Pettersson K., Lövgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991 Sep;37(9):1618–1625. [PubMed] [Google Scholar]
  17. Lundwall A., Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 1987 Apr 20;214(2):317–322. doi: 10.1016/0014-5793(87)80078-9. [DOI] [PubMed] [Google Scholar]
  18. Lövgren J., Piironen T., Overmo C., Dowell B., Karp M., Pettersson K., Lilja H., Lundwall A. Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun. 1995 Aug 24;213(3):888–895. doi: 10.1006/bbrc.1995.2212. [DOI] [PubMed] [Google Scholar]
  19. Mitrunen K., Pettersson K., Piironen T., Björk T., Lilja H., Lövgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem. 1995 Aug;41(8 Pt 1):1115–1120. [PubMed] [Google Scholar]
  20. Nilsson O., Peter A., Andersson I., Nilsson K., Grundström B., Karlsson B. Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA. Br J Cancer. 1997;75(6):789–797. doi: 10.1038/bjc.1997.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Oesterling J. E., Jacobsen S. J., Klee G. G., Pettersson K., Piironen T., Abrahamsson P. A., Stenman U. H., Dowell B., Lövgren T., Lilja H. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol. 1995 Sep;154(3):1090–1095. doi: 10.1016/s0022-5347(01)66984-2. [DOI] [PubMed] [Google Scholar]
  22. Pettersson K., Piironen T., Seppälä M., Liukkonen L., Christensson A., Matikainen M. T., Suonpä M., Lövgren T., Lilja H. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex. Clin Chem. 1995 Oct;41(10):1480–1488. [PubMed] [Google Scholar]
  23. Piironen T., Lövgren J., Karp M., Eerola R., Lundwall A., Dowell B., Lövgren T., Lilja H., Pettersson K. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem. 1996 Jul;42(7):1034–1041. [PubMed] [Google Scholar]
  24. Rajakoski K., Piironen T., Pettersson K., Lövgren J., Karp M. Epitope mapping of human prostate specific antigen and glandular kallikrein expressed in insect cells. Prostate Cancer Prostatic Dis. 1997 Sep;1(1):16–20. doi: 10.1038/sj.pcan.4500206. [DOI] [PubMed] [Google Scholar]
  25. Schedlich L. J., Bennetts B. H., Morris B. J. Primary structure of a human glandular kallikrein gene. DNA. 1987 Oct;6(5):429–437. doi: 10.1089/dna.1987.6.429. [DOI] [PubMed] [Google Scholar]
  26. Stamey T. A., Yang N., Hay A. R., McNeal J. E., Freiha F. S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8;317(15):909–916. doi: 10.1056/NEJM198710083171501. [DOI] [PubMed] [Google Scholar]
  27. Stenman U. H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991 Jan 1;51(1):222–226. [PubMed] [Google Scholar]
  28. Stratikos E., Gettins P. G. Major proteinase movement upon stable serpin-proteinase complex formation. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):453–458. doi: 10.1073/pnas.94.2.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Vihinen M. Modeling of prostate specific antigen and human glandular kallikrein structures. Biochem Biophys Res Commun. 1994 Nov 15;204(3):1251–1256. doi: 10.1006/bbrc.1994.2597. [DOI] [PubMed] [Google Scholar]
  30. Villoutreix B. O., Getzoff E. D., Griffin J. H. A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci. 1994 Nov;3(11):2033–2044. doi: 10.1002/pro.5560031116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Villoutreix B. O., Lilja H., Pettersson K., Lövgren T., Teleman O. Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building. Protein Sci. 1996 May;5(5):836–851. doi: 10.1002/pro.5560050505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wilczynska M., Fa M., Karolin J., Ohlsson P. I., Johansson L. B., Ny T. Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nat Struct Biol. 1997 May;4(5):354–357. doi: 10.1038/nsb0597-354. [DOI] [PubMed] [Google Scholar]
  33. Young C. Y., Andrews P. E., Montgomery B. T., Tindall D. J. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry. 1992 Jan 28;31(3):818–824. doi: 10.1021/bi00118a026. [DOI] [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES